These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38479497)

  • 61. Preservation of renal function in cardiac surgery patients with low cardiac output syndrome: levosimendan vs beta agonists.
    Guerrero Orriach JL; Navarro Arce I; Hernandez Rodriguez P; Raigón Ponferrada A; Malo Manso A; Ramirez Aliaga M; Ramirez Fernandez A; Escalona Belmonte JJ; Bellido Estevez I; Gomez Luque A; Barrera Serrano R; Toledo Medina CS; Rubio Navarro M; Cruz Mañas J
    BMC Anesthesiol; 2019 Nov; 19(1):212. PubMed ID: 31735161
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Levosimendan in cardiac amyloidosis: Unveiling promising paths.
    Faggiano A; Carugo S; Sinagra G; Merlo M
    Int J Cardiol; 2024 Jul; 406():131994. PubMed ID: 38575001
    [No Abstract]   [Full Text] [Related]  

  • 63. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
    Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
    Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function.
    John B; Babu M; Shaji S; Abraham S; Abdullakutty J
    Indian Heart J; 2021; 73(3):372-375. PubMed ID: 34154760
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials.
    Long YX; Cui DY; Kuang X; Hu Y; Hu S; Wang CP; Liu ZZ
    Expert Opin Drug Saf; 2021 Nov; 20(11):1411-1420. PubMed ID: 34214005
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan.
    Qarawani D; Cohen A; Nahir M; Hasin Y
    Int J Cardiol; 2013 Sep; 168(1):237-42. PubMed ID: 23063476
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure.
    d'Humières T; Fard D; Damy T; Roubille F; Galat A; Doan HL; Oliver L; Dubois-Randé JL; Squara P; Lim P; Ternacle J
    Arch Cardiovasc Dis; 2018 Oct; 111(10):582-590. PubMed ID: 29709420
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Levosimendan for Hemodynamic Support after Cardiac Surgery.
    Landoni G; Lomivorotov VV; Alvaro G; Lobreglio R; Pisano A; Guarracino F; Calabrò MG; Grigoryev EV; Likhvantsev VV; Salgado-Filho MF; Bianchi A; Pasyuga VV; Baiocchi M; Pappalardo F; Monaco F; Boboshko VA; Abubakirov MN; Amantea B; Lembo R; Brazzi L; Verniero L; Bertini P; Scandroglio AM; Bove T; Belletti A; Michienzi MG; Shukevich DL; Zabelina TS; Bellomo R; Zangrillo A;
    N Engl J Med; 2017 May; 376(21):2021-2031. PubMed ID: 28320259
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preoperative levosimendan in heart failure patients undergoing noncardiac surgery.
    Katsaragakis S; Kapralou A; Markogiannakis H; Kofinas G; Theodoraki EM; Larentzakis A; Menenakos E; Theodorou D
    Neth J Med; 2008 Apr; 66(4):154-9. PubMed ID: 18424862
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use.
    Tasouli A; Papadopoulos K; Antoniou T; Kriaras I; Stavridis G; Degiannis D; Geroulanos S
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):629-33. PubMed ID: 17702589
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unlocking the Therapeutic Symphony: A Systematic Review Exploring the Role of Levosimendan in the Management of Heart Failure.
    Ali R; Sajjad W; Mushtaq I; Farooqi H; Sohail A; Wazir Khan H; Tabasum P; Haseeb A; Ismail WU
    Cureus; 2024 Jun; 16(6):e62799. PubMed ID: 39036117
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
    Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
    Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A
    Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.